Nigeria’s largest publicly listed drugmakers are pushing ahead with efforts to surmount the pain of foreign exchange scarcity in a bid to maintain earnings growth, BusinessDay’s findings have shown.
BusinessDay’s findings showed Fisdon, GlaxoSmithKline Consumer Nigeria Plc, May & Baker
```
Members Only
Login or create an account to continue
This article is available to registered BusinessDay readers. Please login if you already have an account, or create a new account to continue reading.
New to BusinessDay? Register now and start reading.
```
